Levi & Korsinsky, LLP is investigating Alcobra Ltd. (“Alcobra” or the
“Company”) (NasdaqGM: ADHD) in connection with possible violations of
federal securities laws by the Board of Directors of the Company.
To get more information, click here: http://zlk.9nl.com/alcobra-adhd.
There is no cost or obligation to you.
On October 6, 2014, the Company announced topline results from its Phase
III study of experimental drug MDX for the treatment of Adult ADHD,
declaring that the drug demonstrated a statistically significant
improvement in ADHD symptoms. Then on October 22, 2014, the Company
announced that the study did not, in fact, demonstrate said improvement.
If you own common stock in Alcobra and wish to obtain additional
information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/alcobra-adhd.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Copyright Business Wire 2014